In prostate tumours, inhibiting CXCR-6 expression can interrupt the differentiation of MSCs into CAFs and decrease the CXCL-12 secretion of CAFs via Erk and NF-κB signalling, and knockdown of CXCL16 in vitro also inhibits the formation of CAFs [31]. This evidence concerns the gene CXCL16 and prostate neoplasm.